Role of serum alpha-Klotho and FGF-23 in cardiovascular calcification


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim: To determine the association between the level of alpha-Klotho, FGF-23 and the presence of structural and functional cardiovascular abnormalities in dialysis patients. Materials and Methods: Eighty-three patients from two dialysis centers. Initial assessment included medical history, anthropometric measures, laboratory tests, echocardiography and plain abdominal X-ray. Results: Serum levels of alpha-Klotho and FGF-23 were measured in a cohort of dialysis patients. Reduction of alpha-Klotho concentrations correlated with the left ventricular hypertrophy of (LVH) as assessed by echocardiography and with the abdominal aorta calcification as assessed from abdominal x-ray in lateral view. Changes in the levels of FGF-23 have not shown a similar correlation. Conclusion: Alpha-Klotho can be used as a marker for cardiovascular disease in dialysis patients.

Full Text

Restricted Access

References

  1. Levey A.S., Atkins R., Coresh J. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes // Kidney Int. - 2007. - Vol. 72. - P. 247-259
  2. U.S. Renal Data System. Bethesda, MD: 2010. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
  3. Mann J.F., Gerstein H.C., Pogue J. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial//Ann Intern Med. - 2001. - Vol. 134. - P. 629-636.
  4. Shimada T., Hasegawa H., Yamazaki Y. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis // J Bone Miner Res. - 2004. - Vol. 19. - P. 429-435
  5. Pavik I., Jaeger P., Ebner L. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study // Nephrol Dial Transplant. - 2013. - Vol. 28. - P. 352-359.
  6. Kuro-o M. Klotho in health and disease // Curr Opin Nephrol Hypertens. -2012. - Vol. 21. - P. 362-368.
  7. Lim K., Lu T.S., Molostvov G. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23 // Circulation. - 2012. - Vol. 125. - P. 2243-2255
  8. Imura A., Iwano A., Tohyama O. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane // FEBS Lett. - 2004. - Vol. 565. - P. 143-147.
  9. Hu M.C., Shi M., Zhang J. Klotho deficiency causes vascular calcification in chronic kidney disease // J Am Soc Nephrol. - 2011. - Vol. 22. - P. 124-136.
  10. Chen H.C., Lim L.M., Chang J.M. Save life and improve quality: report from the 5th Congress of International Society for Hemodialysis // Hemodial Int. - 2014 Jan. - Vol. 18(1). - P. 163-71.
  11. Urena Torres P., Friedlander G., de Vernejoul M.C. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients // Kidney Int. - 2008 Jan. - Vol. 73(1). - P. 102-107
  12. Miao L.-Y., Zhu B. Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis // Exp Ther Med. - 2014 Apr. - Vol. 7(4). - P. 947-952
  13. Nasrallah M.M., El-Shehaby A.R., Salem M.M. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients//Nephrol Dial Transplant. - 2010 Aug. - Vol. 25(8). - P. 2679-85.
  14. M.M. NasrAllah, A.R. El-Shehaby. The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers//Nephron Extra. - 2013 Jan-Dec. - Vol. 3(1). - P. 106-112
  15. Литвинов А.С., Батюшин М.М., Литвинова Л.И. (Руденко). Проблемы биосовместимости диализной терапии// Нефрология. - 2013. - Т.17. - № 5. - C. 27-34.
  16. Yamamoto M., Clark J.D., Pastor J.V. Regulation of oxidative stress by the anti-aging hormone klotho // J Biol Chem. - 2005. - Vol. 280. - P. 38029- 38034.
  17. Olivecrona S., Gunnarsson I. FGF23, Albuminuria, and Disease Progression in Patients with Chronic IgA Nephropathy // Clin J Am Soc Nephrol. - 2012. - May; Vol. 7(5). - P. 727-734.
  18. Kuro-o M. Klotho in health and disease // Curr Opin Nephrol Hypertens. - 2012. - Vol. 21. - P. 362-368.
  19. Dai B., David V., Martin A. A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model // PLoS One. - 2012. - Vol. 7. - P. 44161.
  20. Urena Torres P., Friedlander G., de Vernejoul M.C. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients // Kidney Int. - 2008 Jan. - Vol. 73(1). - P. 102-107.
  21. Miao L.-Y., Zhu B. Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis // Exp Ther Med. - 2014. - Apr; Vol. 7(4). - P. 947-952.
  22. Imura A., Iwano A., Tohyama O. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane // FEBS Lett. - 2004. - Vol. 565. - P. 143-147.
  23. Hu M.C., Shi M., Zhang J. Klotho deficiency causes vascular calcification in chronic kidney disease // J Am Soc Nephrol. - 2011. - Vol. 22. - P. 124-136.
  24. Батюшин М.М., Галушкин А.А., Руденко Л.И. Особенности течения хронической почечной недостаточности, осложненной вторичным гиперпаратиреозом // Медицинский вестник Юга России. - 2012. - № 1. - C. 74-76.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies